IDEXX Laboratories Announces Second Quarter Results

WESTBROOK, Maine, July 23, 2013 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the second quarter of 2013 increased 5.0% to $352.6 million, from $335.6 million for the second quarter of 2012. Organic revenue growth[1] was 5.5% versus the prior year period. Earnings per diluted share ("EPS") for the quarter ended June 30, 2013 increased 9% to $0.99, compared to $0.91 for the same period in the prior year.

(Logo:  http://photos.prnewswire.com/prnh/20110602/NE13041LOGO)

"I am pleased with the Companion Animal Group acceleration in sequential quarter organic revenue growth from 3.6% in the first quarter to 6.8% in the second quarter, reflecting strong growth in instrument consumables and reference lab services," said Jonathan Ayers, the Company's Chairman and Chief Executive Officer. "Our confidence in a projected 10% organic revenue growth in the second half of the year comes from a favorable compare to the second half of 2012, the impact of increased sales capacity for digital and customer information management systems sales, the growing adoption of VetConnect® PLUS with its unique patient-centric approach to diagnostic information and our transformation of the North American diagnostic sales organization."

"We are ahead of plan with our sales force transformation for companion animal diagnostics in North America, which makes up approximately 50% of our revenue. Twenty percent of our sales representatives in North America transitioned to their new customer-centric role as Veterinary Diagnostic Consultants during the second quarter. These representatives demonstrated their ability, in the third month after their role change, to increase the number of customer calls on average by almost 60% per representative as a result of this new territory model, and achieved sales performance equivalent to the old model even though they were new to their roles. Currently, we are also ahead of plan in hiring experienced professionals to expand our field presence, increasing our North American diagnostic field force by 14% in the past three months. Training has recently been completed for new representatives as well as the second (and final) wave of existing field representatives and they are now fully in their new roles," commented Ayers.

"We have now activated VetConnect PLUS, our innovative cloud-based service that provides the most recent diagnostic results in the context of a patient's complete diagnostic history, in 8,500 practices in North America, including several hundred in Canada subsequent to its launch in this important country on July 1st," Ayers added. "We are also on track to continue to expand VetConnect PLUS internationally, with expected launches in the United Kingdom and Australia by early 2014."

"There are several exciting new developments in our Rapid Assay product line, most notably our new SNAP Pro™ mobile device. This new offering automates the SNAP® test as well as pushes results automatically to VetConnect PLUS, resulting in improved staff efficiency and customer savings. The unique diagnostic information provided by our widely-used SNAP tests via SNAP Pro will expand the comprehensive nature of the patient's diagnostic history in VetConnect PLUS and allow for easy sharing of client-friendly electronic summaries of SNAP test results. We will begin taking orders for SNAP Pro in the fourth quarter of 2013 with delivery expected early in the first quarter of 2014," commented Ayers.

Revenue Performance

Please refer to the table below entitled "Revenues and Revenue Growth Analysis by Product and Service Categories" in conjunction with the following discussion.

Companion Animal Group. Companion Animal Group ("CAG") revenues for the second quarter of 2013 were $295.8 million compared to $278.3 million for the second quarter of 2012. Organic revenue growth of 6.8% versus the prior year period was due primarily to an increase in sales volumes and net sales prices in our reference laboratories and to higher sales of consumables used with our Catalyst Dx® instrument. Higher sales volumes were driven by the acquisition of new customers and increased testing volumes from existing customers. Changes in foreign currency exchange rates reduced revenue growth by 0.9%, which was partly offset by revenue from acquisitions.

Water. Water revenues for the second quarter of 2013 were $22.4 million compared to $22.0 million for the second quarter of 2012. Organic revenue growth of 2.3% resulted from higher average unit sales prices due primarily to higher relative sales of our Colilert® product and accessories in geographies where these products are sold at higher prices. Changes in foreign currency exchange rates reduced revenue growth by 0.5%.

Livestock, Poultry and Dairy. Livestock, Poultry and Dairy ("LPD") revenues for the second quarter of 2013 were $28.3 million compared to $28.6 million for the second quarter of 2012. The 0.9% decline in organic revenue versus the prior year period resulted from lower sales volumes of certain bovine tests resulting from changes in Bovine Spongiform Encephalopathy ("BSE") testing requirements in the European Union and lower testing levels from certain government programs. This unfavorable factor was partly offset by higher sales volumes of Dairy SNAP® tests used for the detection of antibiotic residues in milk and as well as certain poultry tests. Changes in foreign currency exchange rates did not have a significant impact on reported revenue.

Additional Operating Results for the Second Quarter

Gross profit for the second quarter of 2013 increased $13.0 million, or 7.0%, to $197.7 million from $184.7 million for the second quarter of 2012. As a percentage of total revenue, gross profit increased slightly to 56.1% from 55.0% in the prior year period. The increase in the gross profit percentage was due primarily to efficiencies realized throughout our reference laboratory operations and as well as price increases in our reference laboratories and, to a lesser extent, for consumables used with our VetLab® instruments. These favorable factors were partly offset by the unfavorable impact of currency as hedging losses more than offset the net favorable impact of changes in foreign currency exchange rates.

Selling, general and administrative ("SG&A") expense for the second quarter of 2013 was $96.8 million, or 27.4% of revenue, compared to $88.8 million, or 26.5% of revenue, for the second quarter of 2012. The increase in SG&A expense was due primarily to increased personnel-related costs. Research and development ("R&D") expense for the second quarter of 2013 was $22.2 million, or 6.3% of revenue, compared to $20.1 million, or 6.0% of revenue for the second quarter of 2012. The increase in R&D expense resulted primarily from higher consulting and external development costs and increased personnel-related costs. 

Income from operations for the second quarter of 2013 increased 3.9% to $78.8 million, or 22.3% of revenue, compared to $75.8 million, or 22.6% of revenue, for same period of the prior year.

Supplementary Analysis of Results

The accompanying financial tables provide more information concerning our revenue and other operating results for the three and six months ended June 30, 2013.

Outlook for 2013

The Company provides the following updated guidance for the full year of 2013. The guidance reflects an assumption that the value of the U.S. dollar relative to other currencies will remain at our current assumptions of the euro at $1.30, the British pound at $1.52, the Canadian dollar at $0.96, the Australian dollar at $0.93 and the Japanese Yen at ¥ 99 to the U.S. dollar for the balance of 2013. Based on these assumptions, a 1% strengthening of the U.S. dollar would decrease revenue by approximately $5 million and operating profit by approximately $0.8 million on an annual basis. Fluctuations in foreign currency exchange rates from current assumptions could have a significant positive or negative impact on our actual results of operations for 2013.

  • Revenues for the full year are expected to be $1.37 billion to $1.38 billion reflecting expected full year organic revenue growth of 7.0% to 7.5%, down from previous guidance of 7.5% to 8.0% due to organic revenue growth in the second quarter and an anticipated reduction in capital equipment sales relative to previous expectations.  Reported revenue growth is projected at 6.0% to 6.5% which is down from our previous guidance of 7.0% to 7.5% due to the reduction in expected full year organic revenue growth and unfavorable changes in foreign currency exchange rates.
  • EPS for the full year are expected to be $3.42 to $3.48 compared to our previous guidance of $3.40 to $3.46.  The increase in EPS from previous guidance is due to revised share count estimates reflecting our latest assumptions on share repurchase.
  • Free cash flow for the full year is expected to be approximately 95% to 100% of net income compared to our previous guidance of 100% to 105% of net income due to higher anticipated capital expenditures.
  • Capital expenditures are expected to be approximately $90 million.

Conference Call and Webcast Information

IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (Eastern) to discuss its second quarter results and management's outlook. To participate in the conference call, dial 1-612-332-0228 or 1-800-230-1766 and reference confirmation code 297861. An audio replay will be available through July 30, 2013 by dialing 1-320-365-3844 and referencing replay code 297861.

The call will also be available via live or archived webcast on the IDEXX Laboratories' web site at http://www.idexx.com.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,400 people and offers products to customers in over 175 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company's ability to achieve cost improvements in its worldwide network of laboratories and in the manufacture of in-clinic instruments;the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to manufacture complex biologic products; the impact of a weak economy on demand for the Company's products and services; the effectiveness of the Company's sales and marketing activities; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of a change in the status of one of the Company's distributors on the Company's results of operations;the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; the impact of competition, technological change, veterinary hospital consolidation, and the prevalence of buying consortiums on the markets for the Company's products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the impact of the Company's inexperience and small scale in the human point-of-care market; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; the effects of interruptions to the Company's operations due to natural disasters or system failures; the impact of any class action litigation due to stock price volatility; the effect on the Company's stock price if quarterly or annual operations results do not meet expectations of market analysts or investors in future periods; potential exposures related to our worldwide provision for income taxes and the potential loss of tax incentives and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company's results to differ materially from those expressed or suggested in any forward-looking statement. Readers are advised to review the Company's filings with the Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via the Company's website at www.idexx.com.

[1] Organic revenue is not a measure defined by generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to herein as a non-GAAP measure. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. Organic revenue growth for the second quarter of 2013 excludes the impact of changes in foreign currency exchange rates, which reduced revenue growth by 0.8% and revenue from business acquisitions, which contributed 0.3% to revenue growth.  See the Supplementary Analysis of Results below for a reconciliation of reported revenue growth to organic revenue growth.

Contact: Ed Garber, Director – Investor Relations, 1-207-556-8155








IDEXX Laboratories, Inc. and Subsidiaries







Consolidated Statement of Operations







Amounts in thousands except per share data (Unaudited)

















Three Months Ended


Six Months Ended




  June 30, 

  June 30, 


  June 30, 

  June 30, 




2013

2012


2013

2012

Revenue:

Revenue


$ 352,583

$ 335,649


$ 684,688

$ 658,325

Expenses and








Income:

Cost of revenue


154,885

150,960


303,018

298,862


Gross profit


197,698

184,689


381,670

359,463


Sales and marketing


57,896

54,539


117,294

112,171


General and administrative


38,858

34,275


80,488

70,453


Research and development


22,181

20,058


43,939

40,615


Income from operations


78,763

75,817


139,949

136,224


Interest expense, net


(735)

(446)


(1,125)

(1,203)


Income before provision for income taxes


78,028

75,371


138,824

135,021


Provision for income taxes


24,029

24,051


39,959

42,967

Net Income:

Net income


53,999

51,320


98,865

92,054


Less: Noncontrolling interest in subsidiary's








earnings (losses)


4

3


11

(6)


Net income attributable to stockholders

$ 53,995

$ 51,317


$ 98,854

$ 92,060


Earnings per share: Basic


$ 1.01

$ 0.93


$ 1.83

$ 1.67


Earnings per share: Diluted


$ 0.99

$ 0.91


$ 1.80

$ 1.63


Shares outstanding: Basic


53,670

55,079


54,125

55,143


Shares outstanding: Diluted


54,386

56,211


54,955

56,345









 








IDEXX Laboratories, Inc. and Subsidiaries







Selected Operating Information (Unaudited)


















Three Months Ended


Six Months Ended




June 30,  

June 30,  


June 30,  

June 30,  




2013

2012


2013

2012

Operating

Gross profit


56.1%

55.0%


55.7%

54.6%

Ratios (as a

Sales, marketing, general and







percentage of

administrative expense


27.4%

26.5%


28.9%

27.7%

revenue):

Research and development expense


6.3%

6.0%


6.4%

6.2%


Income from operations(1)


22.3%

22.6%


20.4%

20.7%

















International

International revenue (in thousands)


$       147,233

$       135,950


$       282,764

$       268,234

Revenue:

International revenue as percentage of








total revenue


41.8%

40.5%


41.3%

40.7%









(1)Amounts presented may not sum due to rounding.






 








IDEXX Laboratories, Inc. and Subsidiaries







Segment Information







Amounts in thousands (Unaudited)


















Three Months Ended


Three Months Ended




June 30,  

Percent of


June 30,  

Percent of




2013

Revenue


2012

Revenue

Revenue:

CAG


$       295,834



$       278,294



Water


22,384



21,983



LPD


28,278



28,601



Other


6,087



6,771



Total


$       352,583



$       335,649










Gross Profit:

CAG


$       161,704

54.7%


$       147,908

53.1%


Water


15,044

67.2%


14,794

67.3%


LPD


15,254

53.9%


17,246

60.3%


Other


3,069

50.4%


3,000

44.3%


Unallocated Amounts


2,627

N/A


1,741

N/A


Total


$       197,698

56.1%


$       184,689

55.0%









Income from








Operations:

CAG


$         63,358

21.4%


$         59,768

21.5%


Water


9,913

44.3%


10,196

46.4%


LPD


3,215

11.4%


5,673

19.8%


Other


841

13.8%


387

5.7%


Unallocated Amounts


1,436

N/A


(207)

N/A


Total


$         78,763

22.3%


$         75,817

22.6%









































Six Months Ended


Six Months Ended




June 30,  

Percent of


 June 30,  

Percent of




2013

Revenue


2012

Revenue

Revenue:

CAG


$       572,774



$       546,367



Water


43,050



41,565



LPD


56,317



57,717



Other


12,547



12,676



Total


$       684,688



$       658,325










Gross Profit:

CAG


$       311,942

54.5%


$       287,309

52.6%


Water


28,538

66.3%


27,761

66.8%


LPD


31,130

55.3%


35,169

60.9%


Other


6,257

49.9%


5,576

44.0%


Unallocated Amounts


3,803

N/A


3,648

N/A


Total


$       381,670

55.7%


$       359,463

54.6%









Income from








Operations:

CAG


$       114,666

20.0%


$       106,686

19.5%


Water


18,268

42.4%


18,491

44.5%


LPD


8,051

14.3%


11,690

20.3%


Other


1,276

10.2%


174

1.4%


Unallocated Amounts


(2,312)

N/A


(817)

N/A


Total


$       139,949

20.4%


$       136,224

20.7%









 


IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories

Amounts in thousands (Unaudited)


















Net Revenue

Three

Months

Ended

June 30,

2013



Three

Months

Ended

June 30,

2012


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic Revenue

Growth (3)






















CAG

$

295,834


$

278,294


$

17,540


6.3%


(0.9%)


0.4%


6.8%

Water


22,384



21,983



401


1.8%


(0.5%)


-


2.3%

LPD


28,278



28,601



(323)


(1.1%)


(0.2%)


-


(0.9%)

Other


6,087



6,771



(684)


(10.1%)


0.1%


-


(10.2%)

Total

$

352,583


$

335,649


$

16,934


5.0%


(0.8%)


0.3%


5.5%






















 


Net CAG Revenue

Three

Months

Ended

June 30,

2013



Three

Months

Ended

June 30,

2012


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic Revenue

Growth (3)





















VetLab® instruments

$

20,725


$

23,273


$

(2,548)


(10.9%)


(0.7%)


-



(10.2%)

VetLab® consumables


78,470



68,863



9,607


14.0%


(0.9%)


-



14.9%

VetLab® service and accessories


12,842



12,107



735


6.1%


(2.9%)


-



9.0%

Rapid assay products


46,057



45,577



480


1.1%


(0.8%)


-



1.9%

Reference laboratory diagnostic and

     consulting services


115,917



106,385



9,532


9.0%


(0.8%)


0.3%



9.5%

Customer information management and

     digital imaging systems


21,823



22,089



(266)


(1.2%)


(0.1%)


3.4%



(4.5%)

Net CAG revenue

$

295,834


$

278,294


$

17,540


6.3%


(0.9%)


0.4%



6.8%



















(1) The percentage change from currency is a non-GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the three months ended June 30, 2013 and the same period of the prior year applied to foreign currency denominated revenues for the three months ended June 30, 2013.


(2) The percentage change from acquisitions is a non-GAAP measure. It represents the percentage change in revenue during the three months ended June 30, 2013 compared to the three months ended June 30, 2012 attributed to acquisitions subsequent to March 31, 2012.


(3) Organic revenue growth is a non-GAAP measure and represents the percentage change in revenue during the three months ended June 30, 2013 compared to the three months ended June 30, 2012 net of acquisitions and the effect of changes in foreign currency exchange rates.


 


IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories

Amounts in thousands (Unaudited)















Net Revenue

Six Months

Ended

June 30,

2013



Six Months

Ended

June 30,

2012


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic Revenue

Growth (3)






















CAG

$

572,774


$

546,367


$

26,407


4.8%


(0.8%)


0.3%


5.3%

Water


43,050



41,565



1,485


3.6%


(0.5%)


-


4.1%

LPD


56,317



57,717



(1,400)


(2.4%)


(0.3%)


-


(2.1%)

Other


12,547



12,676



(129)


(1.0%)


-


-


(1.0%)

Total

$

684,688


$

658,325


$

26,363


4.0%


(0.7%)


0.3%


4.4%












































 


Net CAG Revenue

Six Months

Ended

June 30,

2013



Six Months

Ended

June 30,

2012


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic Revenue

Growth (3)






















VetLab® instruments

$

36,537


$

43,823


$

(7,286)


(16.6%)


(0.8%)


-


(15.8%)

VetLab® consumables


153,992



138,695



15,297


11.0%


(0.8%)


-


11.8%

VetLab® service and accessories


25,178



23,722



1,456


6.1%


(2.9%)


-


9.0%

Rapid assay products


90,140



89,241



899


1.0%


(0.8%)


-


1.8%

Reference laboratory diagnostic and

     consulting services


223,566



208,247



15,319


7.4%


(0.6%)


0.2%


7.8%

Customer information management and 

     digital imaging systems


43,361



42,639



722


1.7%


(0.1%)


3.2%


(1.4%)

Net CAG revenue

$

572,774


$

546,367


$

26,407


4.8%


(0.8%)


0.3%


5.3%






















(1) The percentage change from currency is a non-GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the six months ended June 30, 2013 and the same period of the prior year applied to foreign currency denominated revenues for the six months ended June 30, 2013.


(2) The percentage change from acquisitions is a non-GAAP measure. It represents the percentage change in revenue during the six months ended June 30, 2013 compared to the six months ended June 30, 2012 attributed to acquisitions subsequent to December 31, 2011.


(3) Organic revenue growth is a non-GAAP measure and represents the percentage change in revenue during the six months ended June 30, 2013 compared to the six months ended June 30, 2012 net of acquisitions and the effect of changes in foreign currency exchange rates.


 








IDEXX Laboratories, Inc. and Subsidiaries







Consolidated Balance Sheet







Amounts in thousands (Unaudited)





















June 30,

December 31,







2013

2012

Assets:

Current Assets:








Cash and cash equivalents





$           251,013

$           223,986


Accounts receivable, net





159,119

138,324


Inventories





140,938

140,946


Other current assets





63,832

66,281


Total current assets





614,902

569,537


Property and equipment, net





266,494

245,177


Other long-term assets, net





282,675

288,888


Total assets





$        1,164,071

$        1,103,602

Liabilities and








Stockholders'








Equity:

Current Liabilities:








Accounts payable





$            37,584

$             35,288


Accrued liabilities





123,470

137,746


Debt





368,637

213,107


Deferred revenue





21,980

20,192


Total current liabilities





551,671

406,333


Long-term debt, net of current portion





884

1,394


Other long-term liabilities





61,925

59,618


Total long-term liabilities





62,809

61,012










Total stockholders' equity



549,546

636,223


Noncontrolling interest




45

34


Total equity




549,591

636,257


Total liabilities and stockholders' equity




$        1,164,071

$        1,103,602

























IDEXX Laboratories, Inc. and Subsidiaries







Selected Balance Sheet Information (Unaudited)

















June 30,


March 31,

December 31,


September 30,

June 30,



2013


2013

2012


2012

2012

Selected                  









Balance Sheet

Days sales outstanding (1)

41.2


40.8

39.9


41.7

41.9

Information:

Inventory turns (2)

1.7


1.7

1.8


1.7

1.8










(1)  Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that

      quarter, the result of which is then multiplied by 91.25 days.


(2)  Inventory turns represents inventory-related cost of product sales for the 12 months preceding each quarter-end divided by the inventory balance at the

      end of the quarter.


 








IDEXX Laboratories, Inc. and Subsidiaries







Consolidated Statement of Cash Flows







Amounts in thousands (Unaudited)





















Six Months Ended







June 30,

June 30,







2013

2012

Operating:

Cash Flows from Operating Activities:








Net income





$         98,865

$         92,054


Non-cash charges





35,149

32,458


Changes in assets and liabilities



(28,182)

(39,766)


Tax benefit from share-based compensation arrangements


(5,830)

(5,946)


Net cash provided by operating activities





100,002

78,800

Investing:

Cash Flows from Investing Activities:








Purchases of property and equipment





(43,699)

(24,301)


Proceeds from disposition of pharmaceutical product lines



3,500

3,000


Proceeds from sale of property and equipment




-

45


Acquisition of intangible assets



(659)

(900)


Net cash used by investing activities




(40,858)

(22,156)

Financing:

Cash Flows from Financing Activities:








Borrowings on revolving credit facilities, net



155,500

1,000


Payment of notes payable





(480)

(452)


Repurchases of common stock





(206,335)

(55,006)


Proceeds from the exercise of stock options and employee stock purchase plans


16,420

10,247


Tax benefit from share-based compensation arrangements


5,830

5,946


Net cash used by financing activities




(29,065)

(38,265)


Net effect of changes in exchange rates on cash





(3,052)

(461)


Net increase in cash and cash equivalents





27,027

17,918


Cash and cash equivalents, beginning of period




223,986

183,895


Cash and cash equivalents, end of period





$          251,013

$          201,813

















IDEXX Laboratories, Inc. and Subsidiaries







Free Cash Flow(1)







Amounts in thousands (Unaudited)













Six Months Ended







June 30,

June 30,







2013

2012

Free Cash








Flow:

Net cash provided by operating activities





$         100,002

$          78,800


Royalty prepayment to obtain exclusive patent rights





-

6,250


Financing cash flows attributable to tax benefits from share-based compensation arrangements


5,830

5,946


Purchases of property and equipment





(43,699)

(24,301)


Free cash flow





$           62,133

$          66,695









(1) Free cash flow is a non-GAAP measure. We calculate free cash flow as cash generated from operations, excluding our royalty prepayment in the first quarter of 2012, and tax benefits attributable to share-based compensation arrangements, reduced by our investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations.


 








IDEXX Laboratories, Inc. and Subsidiaries







Common Stock Repurchases







Amounts in thousands except per share data (Unaudited)








Three Months Ended


Six Months Ended




June 30,

June 30,


June 30,

June 30,




2013

2012


2013

2012


Share repurchases during the period


1,652

320


2,384

703


Average price paid per share


$            86.37

$            85.82


$           88.33

$           84.52










Shares remaining under repurchase authorization as of June 30, 2013 totaled 4,575,960.                                 






Share repurchases include shares surrendered by employees in payment for the minimum required withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units.





 

SOURCE IDEXX Laboratories, Inc.



RELATED LINKS
http://www.idexx.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.